Form 4: Abbott Director Roman Boosts Equity Holdings

Abbott Laboratories Director Michael F. Roman acquired 281 stock equivalent units, increasing his beneficial ownership to 5,556 units.

Summary

• Michael F. Roman, a Director of Abbott Laboratories (ABT), acquired 281 stock equivalent units.
• The transaction date for these units was September 30, 2025.
• Each stock equivalent unit was valued at $133.94.
• Following this acquisition, Michael F. Roman beneficially owns a total of 5,556 stock equivalent units.
• These units are credited to a stock equivalent unit account, earning the same return as if invested in Abbott shares.
• Payment for these units is generally made in cash at age 65 or upon retirement from the board.
• The balance of 5,556 units includes those acquired through a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The transaction reflects routine director compensation in equity, which is generally viewed positively as it aligns the director's financial interests with the company's stock performance and shareholder value.

Positives

• The acquisition of stock equivalent units by a director aligns management's interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• The transaction represents a routine compensation mechanism for directors, indicating stable corporate governance practices.

Future Outlook

The filing indicates that stock equivalent units are generally paid in cash at age 65 or upon retirement from the board, outlining a future payout mechanism for this compensation.

Industry Context

Director compensation through equity-linked instruments like stock equivalent units is a common practice across various industries, including healthcare and medical devices, to incentivize long-term performance and align director interests with shareholder value.

Comparison to Industry Standards

• Director compensation through stock equivalent units, which mirror the performance of company shares, is a widely adopted practice in corporate governance to align the interests of board members with those of shareholders.
• The filing does not provide specific details on compensation structures of comparable companies or projects, thus a direct, detailed comparison based solely on this document is not feasible.

Related Party Transactions

• The acquisition of stock equivalent units by Director Michael F. Roman constitutes a related party transaction, as it is a form of compensation provided by the issuer to a member of its board.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of director's financial interests with the company's stock performance, potentially fostering long-term value creation.

Next Steps

• Payment of the stock equivalent units in cash, generally at age 65 or upon retirement from the board.

Key Dates

Keywords

Abbott Laboratories, ABT, Michael F. Roman, Director, Insider Transaction, Form 4, Stock Equivalent Units, Equity Compensation, Beneficial Ownership